BiotechTube

ARD-101

Phase 3Active
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphagia

Conditions

Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome

Trial Timeline

Jul 23, 2024 → Apr 1, 2027

NCT ID
NCT07197034

About ARD-101

ARD-101 is a phase 3 stage product being developed by Aardvark Therapeutics for Hyperphagia. The current trial status is active. This product is registered under clinical trial identifier NCT07197034. Target conditions include Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome.

What happened to similar drugs?

0 of 3 similar drugs in Hyperphagia were approved

Approved (0) Terminated (0) Active (3)
🔄CarbetocinAcadia PharmaceuticalsPhase 3
🔄Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
🔄Placebo + ARD-101Aardvark TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07197034Phase 3Active
NCT05153434Phase 2Completed
NCT05215847Phase 2Completed

Competing Products

3 competing products in Hyperphagia

See all competitors
ProductCompanyStageHype Score
CarbetocinAcadia PharmaceuticalsPhase 3
44
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
41
Placebo + ARD-101Aardvark TherapeuticsPhase 3
34